Status:
TERMINATED
Screening for Atrial Fibrillation in Pulmonary Embolism Study -SAFE-PE Study
Lead Sponsor:
Danderyd Hospital
Collaborating Sponsors:
Karolinska Institutet
Conditions:
Atrial Fibrillation
Pulmonary Embolism
Eligibility:
All Genders
Phase:
NA
Brief Summary
Patients with newly diagnosed pulmonary embolism and high thromboembolic risk will be randomized to screening for atrial fibrillation or standard of care using intermittent ECG registration for at lea...
Detailed Description
Patients included in the study might be referred for an ultrasound of deep vein thrombosis unless this has already been performed. Blood will be drawn in a subset of patients to assess cardiac biomark...
Eligibility Criteria
Inclusion
- Recent pulmonary embolism (within three months)
- Fulfilling Chads-Vasc criteria for life-long oral anticoagulant therapy (2 points for men, and 3 points for women), or age \> 65 years
Exclusion
- Known diagnosis of atrial fibrillation Contra-indication to oral anticoagulant therapy Provoked pulmonary embolism in sub-segmental artery only Active cancer therapy (on-going therapy, recent surgery or life-expectancy below 1 year)
Key Trial Info
Start Date :
September 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03274401
Start Date
September 13 2017
End Date
April 1 2022
Last Update
July 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Danderyd Hospital
Stockholm, Sweden, 182 88